Carcinoma of the Prostate - Management

Risk Stratification and Staging

• Transrectal ultrasound (TRUS) + MRI for local staging
• Bone scan + CT for metastatic assessment
• PSMA PET/CT (Ga-68 PSMA-11 or 18F-DCFPyL) - now preferred for detecting small-volume disease and biochemical recurrence
• Germline genetic testing recommended for high-risk, regional, or metastatic disease; Ashkenazi Jewish ancestry; or relevant family history (BRCA1/2, DNA repair genes)

Localized Disease (Stages I-II)

1. Watchful Waiting / Observation

• For men with life expectancy <10 years or significant competing comorbidities
• No curative intent; treat symptoms as they arise

2. Active Surveillance

• For low-risk, organ-confined cancer
• Protocol: PSA every 6 months, DRE annually, repeat biopsies (potentially every 12 months), MRI spectroscopy consideration
• Ki-67 (proliferation marker) and PTEN loss can identify patients who may need escalation
• Appropriate for many men in their 70s with low-risk disease

3. Radical Prostatectomy

• For clinically localized disease with life expectancy >10 years
• Robot-assisted and laparoscopic approaches preferred over open surgery (less blood loss, shorter hospital stay, lower incontinence and ED rates)
• Extended pelvic lymph node dissection (external iliac vein, pelvic side wall, bladder wall, internal iliac artery nodes) if high probability of nodal involvement
• Generally limited to men <75 years; comparable outcomes to radiation for low-/intermediate-risk disease

4. Radiation Therapy

• External Beam Radiation Therapy (EBRT): Intensity-modulated RT with hypofractionation (19 x 3.4 Gy or ultra-fractionated 7 x 4.1 Gy) are non-inferior to conventional fractionation
• 3D image-guided RT ensures proper daily positioning to minimize bladder and rectal dose
• Proton therapy: more conformal dosing but does not improve clinical outcomes vs. photon EBRT despite higher cost
• Brachytherapy (seed implantation): Alone for low-risk early-stage disease; combined with EBRT for higher-risk disease

Management by Risk Category (Bailey & Love)

High-Risk / Locally Advanced Disease (Stage III)

• Radical prostatectomy + adjuvant/salvage radiation therapy
• Neoadjuvant ADT before surgery and radiation to improve cure rates
• High-intensity focused ultrasound (HIFU), focal cryotherapy, focal laser ablation are experimental and associated with high recurrence - not recommended for routine use

Biochemical Recurrence

• Post-radical prostatectomy: recurrence = PSA ≥0.2 ng/mL confirmed on two occasions (PSA should be undetectable post-op)
• Post-radiation: recurrence = PSA rise >2 ng/mL above post-treatment nadir (PSA nadir can take up to 2 years)
• ~40% of men treated definitively will have biochemical recurrence within 10 years
• Management: salvage radiation (post-prostatectomy), ADT, observation based on PSA doubling time and clinical context

Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

• Bind GnRH receptors -> initial testosterone surge (flare) - pretreat with antiandrogen (bicalutamide, flutamide, nilutamide) if significant metastatic burden

• Direct action, no flare response
• Relugolix associated with ~50% fewer major adverse cardiovascular events vs. leuprolide

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Hormone-Based Agents (continued ADT + novel agent)

• Abiraterone acetate (CYP17 inhibitor) + prednisone - approved pre- and post-chemotherapy
• Enzalutamide (androgen receptor antagonist) - approved pre- and post-chemotherapy
• Darolutamide - approved in nmCRPC and mCRPC

Chemotherapy

• Docetaxel - first-line chemotherapy for mCRPC (was the only life-prolonging therapy through 2010)
• Cabazitaxel - second-generation taxane for post-docetaxel mCRPC

Immunotherapy / Targeted

• Sipuleucel-T - autologous cellular immunotherapy; approved for asymptomatic/minimally symptomatic mCRPC
• Olaparib, Rucaparib - PARP inhibitors for BRCA1/2-mutated mCRPC (FDA-approved monotherapies)
• Abiraterone + olaparib - approved combo for BRCA1/2-mutated mCRPC
• Enzalutamide + talazoparib - approved for BRCA1/2 mutations and other DNA repair pathway mutations
• Pembrolizumab, Dostarlimab - checkpoint inhibitors for MSI-high, MMR-deficient, or high tumor mutational burden tumors (~3% of prostate cancers)

Bone-Targeted / Radiopharmaceutical

• Radium-223 (α-emitter) - for symptomatic bone metastases without visceral disease; survival benefit + bone complication reduction
• 177-Lutetium PSMA-617 (Lu-PSMA) - PSMA-directed radionuclide therapy; extends survival in heavily pre-treated patients. Current meta-analyses confirm significant PSA response and survival benefit (PMID: 39327114, Eur Urol 2025)
• Actinium-225 PSMA (α-therapy) - under active investigation; systematic review/meta-analysis data from 2025 suggest high response rates even post-Lu-PSMA (PMID: 40093902)
• Denosumab or Zoledronic acid - for bone protection in CRPC with bone metastases

Pain Management (Bone Metastases)

• Accurate diagnosis essential (rule out non-cancer causes: degenerative disease, spinal stenosis)
• NSAIDs, opioids as needed
• Radium-223 for bone pain from metastases
• Local RT for focal painful lesions

Summary Treatment Table (Goldman-Cecil)

Key Points

• PSA nadir after ADT at 6-8 months is a key prognostic marker; PSA nadir >4 ng/mL predicts markedly inferior survival
• Germline testing (BRCA1/2, ATM, CDK12, MMR genes) now guides systemic therapy selection
• Sequencing of agents in mCRPC remains an active area of research - consultation with a specialist in advanced prostate cancer is recommended
• Definitive therapy (surgery/radiation) is generally reserved for men with life expectancy >10 years and typically limited to those ≤75 years
• Screening decisions should factor in age, life expectancy, comorbidity, and patient preference

Recent evidence note: 2025 meta-analyses confirm survival benefit of 177Lu-PSMA therapy in mCRPC (PMID: 39327114, Eur Urol; PMID: 40705094, Eur J Nucl Med). Ac-225 PSMA alpha therapy is emerging as a rechallenge option post-Lu-PSMA (PMID: 40093902, Theranostics 2025).

Ca Prostate Management - EAU Guidelines 2025

Exam-Ready Flowchart

CLINICAL SUSPICION OF PROSTATE CANCER
(PSA raised / abnormal DRE / symptoms)
              │
              ▼
    ┌─────────────────────┐
    │  RISK STRATIFICATION │
    │  PSA + DRE + mpMRI   │
    │  (avoid unnecessary  │
    │   biopsy by mpMRI)   │
    └─────────────────────┘
              │
    If biopsy needed → Targeted + Systematic biopsy
              │
              ▼
    ┌──────────────────────────────────────────────────┐
    │          HISTOLOGY: PROSTATE ADENOCARCINOMA       │
    │     Graded by ISUP Grade Group (GG 1–5)          │
    │     [GG1=Gleason 6 | GG2=3+4 | GG3=4+3          │
    │      GG4=8 | GG5=9-10]                           │
    └──────────────────────────────────────────────────┘
              │
              ▼
    STAGING → Bone scan + CT (conventional)
              OR PSMA PET/CT (preferred, if available)
              │
              ▼
┌─────────────────────────────────────────────────────────────┐
│                   EAU RISK CLASSIFICATION                   │
├───────────────┬────────────────────────┬────────────────────┤
│   LOW RISK    │   INTERMEDIATE RISK    │    HIGH RISK /     │
│               │                        │  LOCALLY ADVANCED  │
│ PSA <10 AND   │  PSA 10–20 OR          │  PSA >20 OR        │
│ GG1 (GS≤6)   │  GG2-3 (GS 7) OR       │  GG4-5 (GS≥8) OR  │
│ AND cT1-cT2a  │  cT2b-cT2c             │  cT3-cT4           │
└───────────────┴────────────────────────┴────────────────────┘
        │                   │                        │
        ▼                   ▼                        ▼

BRANCH 1: LOW-RISK LOCALIZED

LOW RISK (cM0)
      │
      ├──► Life expectancy < 10 yrs → WATCHFUL WAITING
      │
      └──► Life expectancy > 10 yrs → ACTIVE SURVEILLANCE ← (PREFERRED)
                                        │
                                        │ PSA q6 months
                                        │ DRE annually
                                        │ Repeat biopsy / MRI
                                        │
                                        ▼ (if progression)
                              Curative therapy (RP or RT)

BRANCH 2: INTERMEDIATE-RISK LOCALIZED

INTERMEDIATE RISK (cM0)
        │
        ├──► Life expectancy < 10 yrs → WATCHFUL WAITING
        │
        ├──► Favorable intermediate → Active Surveillance (discuss)
        │
        └──► Active treatment:
              │
              ├── RADICAL PROSTATECTOMY (RP)
              │     ± ePLND (extended pelvic lymph node dissection)
              │
              └── EBRT (IMRT/VMAT + IGRT)
                    ± Short-course ADT (4–6 months)
                    ± Brachytherapy boost (LDR or HDR)

BRANCH 3: HIGH-RISK / LOCALLY ADVANCED

HIGH RISK / LOCALLY ADVANCED (cT3-T4, cM0)
              │
              ├──► Life expectancy < 10 yrs → WATCHFUL WAITING
              │
              └──► Active treatment (MULTIMODAL):
                        │
                        ├── RADICAL PROSTATECTOMY + ePLND
                        │     (selected patients, part of multimodal Rx)
                        │
                        └── EBRT + LONG-COURSE ADT (≥2 years)
                              ± Brachytherapy boost
                              ± Abiraterone (if ≥2 high-risk features)

              ⚠ Do NOT offer ADT monotherapy to asymptomatic patients
                who can receive local treatment
              ⚠ Cryotherapy / HIFU only within clinical trials

BRANCH 4: BIOCHEMICAL RECURRENCE (BCR) after curative Rx

PSA RISE after definitive therapy
              │
        ┌─────┴──────────────────────┐
        │                            │
   After RP                    After EBRT
  (PSA ≥ 0.2 ng/mL x2)       (PSA nadir + 2 ng/mL)
        │                            │
        ▼                            ▼
   PSMA PET/CT                  PSMA PET/CT
   (if PSA > 0.2 ng/mL)        + mpMRI + biopsy

              │
    ┌─────────┴──────────────┐
    │                        │
  cM0                      cM+ (or mHSPC)
    │                        │
    ▼                        ▼
EAU LOW risk BCR:        Manage as
PSA-DT >1yr, GG<4        METASTATIC (see below)
→ Monitoring

EAU HIGH risk BCR:
PSA-DT <1yr OR GG≥4
→ Salvage RT + ADT
   (if post-RP)
→ ADT ± systemic agent
   (if post-RT)

BRANCH 5: METASTATIC HORMONE-SENSITIVE (mHSPC / M1)

METASTATIC HORMONE-SENSITIVE PCa (mHSPC)
              │
              ▼
     ADT (CASTRATION) = backbone
     ┌─────────────────────────────────────────────────┐
     │ GnRH Agonist (leuprolide, goserelin, triptorelin)│
     │    → pretreat with antiandrogen to prevent FLARE │
     │ GnRH Antagonist (degarelix IV / relugolix oral)  │
     │    → no flare; relugolix preferred if high CV risk│
     └─────────────────────────────────────────────────┘
              │
              ▼
     ADT ALONE is INSUFFICIENT → ADD systemic agent:
     ┌────────────────────────────────────────────────────────┐
     │ + ABIRATERONE + prednisone    (all volumes)            │
     │ + ENZALUTAMIDE                (all volumes)            │
     │ + APALUTAMIDE                 (all volumes)            │
     │ + DAROLUTAMIDE                (all volumes)            │
     │ + DOCETAXEL                   (high-volume disease)*   │
     │                                                        │
     │ *High-volume = visceral mets OR ≥4 bone mets           │
     │  including ≥1 beyond vertebrae/pelvis                  │
     │                                                        │
     │ + EBRT to prostate PRIMARY if low-volume mHSPC         │
     │   (reduces progression; NOT recommended high-volume)   │
     └────────────────────────────────────────────────────────┘

BRANCH 6: CASTRATION-RESISTANT PCa (CRPC)

DEFINITION: Progression despite testosterone < 50 ng/dL (1.7 nmol/L)
             [PSA rises x3 consecutive, ≥1 week apart, PSA >2 ng/mL]
              │
              ▼
        CONTINUE ADT LIFELONG + add:
              │
    ┌─────────┴─────────────────────────────────────┐
    │                                               │
  Non-metastatic CRPC (nmCRPC)             Metastatic CRPC (mCRPC)
  (M0, PSA rising, high-risk)                        │
    │                                     ┌──────────┴───────────┐
    ▼                                     │                      │
  ENZALUTAMIDE                      No prior              Post-docetaxel
  APALUTAMIDE         (one of)      chemotherapy           progressed
  DAROLUTAMIDE                           │                      │
                                         ▼                      ▼
                               ABIRATERONE+pred          CABAZITAXEL
                               ENZALUTAMIDE              ABIRATERONE
                               DOCETAXEL                 ENZALUTAMIDE
                                    │                         │
                            ──────────────────────────────────
                                         │
                                  BIOMARKER GUIDED:
                            BRCA1/2 → OLAPARIB / RUCAPARIB
                            BRCA1/2 → ABIRATERONE + OLAPARIB
                            MSI-H / MMR-def → PEMBROLIZUMAB
                            PSMA-positive → 177Lu-PSMA-617
                                         │
                            BONE METASTASES:
                            → Radium-223 (α-emitter, no visceral mets)
                            → Denosumab OR Zoledronic acid
                            → Sipuleucel-T (asymptomatic/minimal symptoms)

FOLLOW-UP (after curative therapy)

FOLLOW-UP after RP / RT
        │
        ├── PSA every 3–6 months (first 2 years)
        ├── PSA every 6–12 months (years 2–5)
        ├── PSA annually (after 5 years)
        │
        └── Imaging ONLY if result will change management

Quick Exam Memory Summary

• PSMA PET/CT is now preferred staging for both high-risk AND unfavorable intermediate-risk disease
• ADT monotherapy alone is NOT recommended for asymptomatic patients
• EBRT on primary prostate in mHSPC only for low-volume disease
• Triplet therapy (ADT + ARTA + EBRT) is an option in high-risk mHSPC but randomised data vs. ADT + ARTA alone is lacking
• Relugolix (oral GnRH antagonist) preferred over leuprolide in patients with high cardiovascular risk